Allarity Therapeutics Inc   (ALLR)
Other Ticker:  
Price: $0.3900 $-0.01 -1.590%
Day's High: $0.4025 Week Perf: -3.25 %
Day's Low: $ 0.38 30 Day Perf: -9.93 %
Volume (M): 130 52 Wk High: $ 13.49
Volume (M$): $ 51 52 Wk Avg: $0.98
Open: $0.40 52 Wk Low: $0.07

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Allarity Therapeutics Inc
Allarity Therapeutics Inc. is a biotechnology company headquartered in Denmark. The company focuses on developing personalized medicine and innovative drug discovery solutions for the treatment of cancer. Their proprietary drug response predictor (DRP) technology helps identify which patients are likely to respond positively to certain drug treatments, based on molecular profiling and analysis.

Allarity Therapeutics aims to optimize the use of existing drugs and accelerate the development of new therapies by identifying and targeting specific patient populations that will benefit the most. Their DRP technology evaluates the unique genetic profile of each patient to tailor treatments and improve clinical outcomes. This personalized approach has the potential to significantly improve patient care and reduce healthcare costs by avoiding ineffective treatments.

The company's pipeline includes several drug candidates in various stages of development for targeted cancer treatments. Allarity Therapeutics collaborates with research institutions, academic partners, and pharmaceutical companies to advance their drug development programs. Their goal is to bring effective therapies to the market and improve the lives of cancer patients worldwide.

   Company Address: 24 School Street Boston 2108 MA
   Company Phone Number: 426-4664   Stock Exchange / Ticker: NASDAQ ALLR
   ALLR is expected to report next financial results on March 09, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Management Changes

Allarity Therapeutics Reimagines Personalized Cancer Care Through New Leadership Additions

Published Tue, Dec 12 2023 11:00 AM UTC

Allarity Therapeutics, a clinical-stage pharmaceutical company specializing in the development of personalized oncology therapeutics and companion diagnostics, has announced a significant transition in its leadership. In a recent press release, the company revealed the appointment of Thomas H. Jensen as Interim Chief Executive Officer (CEO) and the engagement of Je...

Allarity Therapeutics Inc

Allarity Therapeutics Inc Surges in Stock Value, but Challenges Lie Ahead for Future Growth

Allarity Therapeutics Inc, a company operating in the Major Pharmaceutical Preparations industry, has recently reported a substantial gain in its stock value over the past week as well as a significant increase for the year 2023. However, scrutiny of the company's financial results reveals certain challenges that could impact its future prospects. This article will explore the implications of these financial findings and how they might impact Allarity Therapeutics Inc going forward.
Solid Stock Gains and NASDAQ Performance:
Allarity Therapeutics Inc has experienced a commendable increase in its stock value, recording a gain of 5.21% over the last seven days. Additionally, when compared to the previous year, the stock has soared by an impressive 91.12% in 2023. Despite these positive figures, it is crucial to note that the stock currently trades on the NASDAQ at a significant 46.5% below its 52-week average. This indicates that there may be some underlying challenges within the company's operations that have yet to be fully addressed.

Allarity Therapeutics Inc

Allarity Therapeutics Inc Faces Operating Deficit of $4.156 Million in Q2 2023, Revealing Potential Decline in Revenue

The Major Pharmaceutical Preparations sector advisors are closely analyzing the financial performance of the second quarter of 2023. Allarity Therapeutics Inc, a prominent player in the industry, has reported an operating deficit of $-4.156 million for the period spanning April to June 30, 2023. Surprisingly, the company has not disclosed any top-line figures for the quarter, indicating a potential decline in revenue.
Comparing this performance to the second quarter of 2022, it is evident that the company has experienced challenges in managing day-to-day operations. As Allarity Therapeutics is primarily in the progress stage, this situation is to be expected. Developing successful revenue sources often involves navigating through certain bumpy periods, and the April to June 30, 2023, period seems to have presented specific challenges, with shortfalls extending to $-7.525 million.

Allarity Therapeutics Inc

Allarity Therapeutics Inc's Lackluster Financial Performance Raises Concerns over Long-Term Viability

Allarity Therapeutics Inc is a healthcare company that is focused on identifying and developing innovative cancer treatments that have the potential to impact the lives of millions of people around the world. The company has been at the forefront of groundbreaking research and development in the field of precision oncology, which is a rapidly emerging area of healthcare that seeks to tailor cancer therapies to the specific genetic profile of a patient's tumor.
Over the past few years, Allarity Therapeutics Inc has made significant progress in advancing its research and development initiatives, which have been aimed at developing new cancer treatments that target the underlying genetic mutations that drive tumor growth. However, despite its research and development successes, the company has struggled to generate significant revenue and profitability, which has left some investors concerned about the long-term prospects of the company.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com